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Abstract 
Purpose: To study the anti-arthritic effect of total anthraquinone from Polygonum cuspidatum (TAPC) 
on type II collagen-induced arthritis (CIA) in rats, and to investigate the underlying mechanism(s). 
Methods: CIA rats were prepared and treated orally with TAPC at doses of 50, 100 and 200 mg/kg/day, 
for 24 days. Paw volume and arthritis score were measured prior to TAPC treatment, and subsequently 
at 3-day intervals on days 3, 6, 9, 12, 15, 18, 21 and 24. Serum levels of TNF-α, IL-6 and IL-17 were 
determined by enzyme-linked immunosorbent assay (ELISA), while synovial tissue TNF-α, IL-6 and IL-
17mRNA expressions were assayed by real time-polymerase chain reaction (RT-PCR). Thymus and 
spleen indices were also determined. 
Results: TAPC (50, 100 and 200 mg/kg) significantly alleviated paw swelling (p < 0.05), arthritis scores 
(p < 0.05) and thymus and spleen indices (p < 0.05) of CIA rats, when compared with the control rats. In 
addition, TAPC significantly decreased serum levels of the pro-inflammatory cytokines TNF-α, IL-6 and 
IL-17 (p < 0.01); and down-regulated their mRNA expressions in synovial tissues (p < 0.01). 
Conclusion: These results suggest that TAPC exerts good anti-arthritic activity in rats, most probably 
via suppression of inflammatory responses. 
 
Keywords: Polygonum cuspidatum, Anthraquinone, Type II collagen-induced arthritis, Pro-inflammatory 
cytokines 
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Rheumatoidarthritis (RA) is a common 
destructive chronic systemic autoimmune 
disease of the joints [1,2]. It usually results in 
chronic proliferative synovitis and infiltration of 
inflammatory cells into the synovial tissue of 
joints, causing joint swelling, destruction of 
cartilage and bone, and disability [3,4]. In 
addition, RA leads to extra cares and economic 
burdens on the family of patients [5]. It’s reported 
that over 0.5 % human beings in the world are 
suffered from the disease of RA [6,7]. Currently, 
drugs used for treating RA include non-steroidal 
anti inflammatory drugs (NSAIDs), disease-
modifying anti-rheumatic drugs, glucocorticoids 
and biological drugs [8]. However, these drugs 
only bring about momentarily amelioration of the 
RA symptoms rather than radical cure. Moreover, 
long term use of these medications is expensive 
and toxic [8,9]. Consequently, there is need to 
find novel therapeutic approaches against RA. 
 
Polygonum cuspidatum, a traditional Chinese 
medicine (TCM), has been used for treating 
inflammatory diseases for thousands of years 
[10,11]. Extensive reports have demonstrated 
that anthraquinones is the most important active 
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constituents of P. cuspidatum [12,13]. In addition, 
previous reports indicated that extracts of P. 
cuspidatum exerted significant anti-arthritic effect 
in rats, which effect was thought to be due to 
their anthraquinone contents [14]. However, to 
date, there are no studies on the anti-arthritic 
potential of active phytochemical constituents of 
P. cuspidatum. Consequently, the present 
investigation was aimed at investigating the anti-
arthritic effect of total anthraquinones from P. 
cuspidatum (TAPC) against type II collagen-





Chemicals and materials  
 
Total anthraquinones of P. cuspidatum (TAPC) 
were obtained from the Hunan Nutra Max Inc. 
(Changsha, China). Chicken type II collagen 
(CII), methotrexate (MTX), and complete 
Freund’s adjuvant (CFA) were products of Sigma 
Co. (Shanghai, China). Rat tumor necrosis factor 
(TNF)-α, interleukin (IL)-6 and rat IL-17 ELISA 
kits were products of Abcam Co. (Cambridge, 
UK). All other chemicals used in this study were 
of analytical reagent grade. 
 
Preparation of CIA rat model and 
experimental protocols 
 
An arthritic rat model was established using type 
II collagen (CII). All the animal experimental 
protocols were according to the international 
standard protocols for the use of laboratory 
animals [15], and were approved by Animal Care 
and Use Committee of Heping Hospital Affiliated 
to Changzhi Medical College (approval ref no. 
KY-2016A-001). 
 
Sixty rats were randomly divided into six groups 
(n=10): normal rats treated with saline alone (10 
mL/kg); CIA control rats (arthritic rats treated with 
saline (10 mL/kg); MTX rats (CIA rats treated 
with 2 mg MTX/kg, 3 times a week); and CIA rats 
treated with TAPC at doses of 20, 100 and 200 
mg/kg. The CIA rats were prepared as reported 
previously [2] with minor modifications. Type II 
collagen (CII) was dissolved in 0.1 mM acetic 
acid (4 mg/mL), and emulsified with an equal 
volume of CFA. Then, the rats were initially 
immunized by subcutaneously injection of the 
CII-CFA emulsion into the tail root (100 μL/rat). 
After 7 days, the rats were secondarily 
immunized by subcutaneous injection of the CII-
CFA emulsion (100 μL/rat). 
 
After 20 days of the initial CII immunization, the 
rats were orally administered saline, MTX and 
different doses of TAP (50, 100 and 200 mg/kg). 
During the observation period, the paw volumes 
of the rats were measured at the start, and then 
on days 3, 6, 9, 12, 15, 18, 21 and 24. Moreover, 
the arthritis scores were determined at the start, 
and subsequently at 3-day intervals on days 3, 6, 
9, 12, 15, 18, 21 and 24. Arthritis was scored 
according to the ordinal rules [2], i.e., 0 = normal, 
1 = obvious swelling or erythema observed in 
one joint, 2 = obvious swelling or erythema 
observed in two joints, 3 = obvious swelling or 
erythema observed in three joints, and 4 = three 
joints affected plus maximal erythema and 
swelling. After 24 days of treatment, the rats 
were weighed, and blood samples were collected 
through orbital blood sampling. Then the rats 
were sacrificed by decapitation, and the thymus 
and spleen were isolated for determination of 
their visceral indices (ratio of thymus or spleen 
wet weight to body weight). Synovial tissues 
were collected for western blot assays. 
 
Determination of serum levels of TNF-α, IL-6 
and IL-17 
 
Blood samples were allowed to clot for 1 h at 
room temperature, and centrifuged for 15 min at 
1800 g to obtain sera. Serum levels of TNF-α, IL-
6 and IL-17 were determined by commercial 
ELISA kits according to manufacturer’s 
instructions. 
 
Determination of TNF-α, IL-6 and IL-17 mRNA 
expressions in synovial tissues  
 
Synovial tissue samples were homogenized in 
liquid nitrogen and the total RNA was isolated by 
RNAiso Plus kits (TaKaRa, Tokyo, Japan). Then, 
cDNA was synthesized by reverse transcription 
with the PrimeScript™ RT reagent Kits (TaKaRa, 
Tokyo, Japan). Then, cDNAs were amplified by 
PCR assays with SYBR Green Mix kits (Bio-Rad, 
Shanghai, China) and the bands were detected 
by real-time PCR Detection System (Bio-Rad, 
Shanghai, China). All the primers used in this 
experiment were synthesized by Sangon Biotech 
(Shanghai, China Table 1). The relative mRNA 
expressions of TNF-α, IL-6 and IL-17 in synovial 





Data are expressed as mean ± SD and were 
evaluated using one-way ANOVA followed by 
Dunnett’s multiple comparisons. SPSS software 
(SPSS for Windows 19.0; IBM Corp., Armonk, 
NY, USA) was used for the analysis, and 
statistical significance was set at p < 0.05. 
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Table 1: Primers used for real-time PCR 
 
Gene 
name Primer sequence Reference 
TNF-
α 
F: 5′-CAGGTTCTGTCCCTTTCACTCACT- [16] 
R: 5′-GTTCAGTAGACAGAAGAGCGTGGT-
IL-6 













TAPC decreases paw swelling and arthritis 
scores in CIA rats 
 
The CIA rats showed obvious symptoms of RA, 
such as paw swelling and higher arthritis scores 
(p < 0.01), when compared with normal, control 
rats (Figures 1 & 2).  These CIA-induced RA 
symptoms were significantly mitigated by 
administration of MTX (p < 0.01). In addition, 
TAPC treatment at doses of 50, 100 and 200 
mg/kg significantly and dose-dependently 
decreased the arthritis scores (p < 0.01) as well 
as paw swelling (p < 0.05, p < 0.01 and p < 0.01, 
respectively) in CIA rats, when compared with 
untreated CIA rats. All these results suggested 
that TAPC might possess notable therapeutic 
effect for treating RA. 
 
TAPC decreases thymus and spleen indices 
in CIA rats 
 
As can be seen from Fig. 3, thymus and spleen 
indices of control rats (CIA rats) were 
significantly higher (p < 0.01) than those of 
normal rats. After treatment with MTX (2 mg/kg, 
3 times a week), both the thymus and the spleen 
indices were decreased (p < 0.01), when 
compared with those of the control rats. Similarly, 
TAPC treatment at the dose of 200 mg/kg 
significantly reduced the thymus and spleen 
indices relative to those of the control rats (p < 
0.01). TAPC administration at a dose of 100 
mg/kg significantly decreased the thymus index 
(p < 0.01), when compared to the control rats. 
 
Figure 1: Effect of TAPC on paw volume changes of CIA rats. Note: Cont: control rats. Norm: normal rats. Data 
are presented as the mean ± SD (n = 10). ##p < 0.01, vs. Norm; *p < 0.05, **p < 0.01, vs. Cont. Day 0 means day 
20 after initial immunization. Key: ◆:Normal, △: Cont, ◇:MTX, ■:50mg/kg, □:100mg/kg,▲:200mg/kg 
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Figure 2: Effect of TAPC on arthritis score changes of CIA rats. Note: Cont: control rats. Norm: normal rats. Data 
are presented as the mean ± SD (n = 10). ##p < 0.01, vs. Norm; *p < 0.05, **p < 0.01, vs. Cont. Day 0 means day 
20 after initial immunization. Key: ◆:Normal, △: Cont, ◇:MTX, ■:50mg/kg, □:100mg/kg,▲:200mg/kg 
 
 
Figure 3: Effects of TAPC on thymus and spleen index in CIA rats. Note: Cont: control rats. Norm: normal rats. 
Data are presented as mean ± SD (n = 10). ##p < 0.01, vs. Norm; *p < 0.05, **p < 0.01, vs. Cont 
 
TAPC decreased serum levels of TNF-α, IL-6 
and IL-17 in CIA rats 
 
Serum levels of TNF-α, IL-6 and IL-17 in 
untreated CIA rats were significantly higher than 
their corresponding levels in normal rats (p < 
0.01). In addition, the levels of the three pro-
inflammatory cytokines were significantly 
reduced in serum of rats treated with MTX. 
Interestingly, TAPC brought about significant and 
dose-dependent decreases in the serum levels 
of the pro-inflammatory cytokines TNF-α and IL-
17 (p < 0.01), when compared to the untreated 
CIA rats. Furthermore, TAPC at doses of 100 
and 200 mg/kg significantly decrease serum 
levels of IL-6 (p < 0.01), relative to the control, 
untreated CIA rats. 
 
TAPC down-regulated TNF-α, IL-6 and IL-17 
mRNA expressions in synovial tissues of CIA 
rats 
 
As shown in Figure 5, compared to normal rats, 
mRNA expressions of the three cytokines were 
significantly elevated in the untreated CIA rats (p 
< 0.01). However, importantly, the present 
results also demonstrated that TTAPC treatment 
(50, 100 and 200 mg/kg) significantly and dose-
dependently down-regulated the expressions of 
the mRNA expressions of TNF-α, IL-6 and IL-17 
mRNAs in synovial tissues (p < 0.01), when 




It has been reported that herbal medicines are 
good potential sources of novel anti-inflammatory 
agents which could be used for treating RA 
[2,18]. In the present work, the anti-arthritic 
activities of TAPC in a CIA rat model were 
studied for the first time, and the results 
demonstrate that TAPC possesses promising 
anti-arthritic potential via inhibition of 
inflammatory responses.  
 
Increasing amount of evidence have demonstra- 
ted that RA is a typical immune mediated chronic 
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Figure 4: Effect of TAPC on serum levels of TNF-α, IL-6 and IL-17 in CIA rats. Note: Cont: control rats. Norm: 
normal rats. Data are presented as mean ± SD (n = 10). ##p < 0.01, vs. Norm; *p < 0.05, **p < 0.01, vs. Cont 
 
 
Figure 5: Effects of TAPC on mRNA expressions of TNF-α, IL-6 and IL-17in synovial tissues of CIA rats. Note: 
Cont: control rats. Norm: normal rats. Data are presented as mean ± SD (n = 10). ##p< 0.01, vs. Norm; *p < 0.05, 
**p < 0.01, vs. Cont 
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Two mature animal models for investigation of 
RA have been developed. These are type II 
collagen-induced arthritis (CIA) and adjuvant-
induced arthritis (AIA) models [2,21]. Studies 
have demonstrated that CIA is a good RA animal 
model with immunological and pathological 
characteristics similar to those of human RA 
patients [21,22]. In the present study, the CIA rat 
model was successfully established, and used 
for evaluating the anti-arthritic effects of TAPC. 
The results obtained revealed that TAPC 
treatment effectively alleviated the CIA-induced 
paw swelling and high arthritis scores in the rats.  
It is well known that the control of inflammatory 
responses is beneficial for inhibiting the 
development of RA [2,19,20]. The results of the 
present study indicate that TAPC can relieve 
inflammatory reactions in CIA rats, as evidenced 
by alleviation of paw swelling and decreases in 
arthritis scores. The present study also 
determined the serum levels of pro-inflammatory 
cytokines TNF-α, IL-6 and IL-17.These cytokines 
stimulate inflammatory reactions in arthritic joints, 
and have been reported to be the potential 
targets for the effective treatment of RA [1,2,23]. 
Treatment with TAPC effectively decreased the 
serum levels of these three cytokines in the CIA 
rats. Consistent with this finding, TAPC also 
significantly and dose-dependently down-
regulated expressions of TNF-α, IL-6 and IL-17 




The results of the present investigation indicate 
that TAPC possesses good anti-arthritic 
properties in rats, through a mechanism involving 
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